Cover Image

Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (...

Full description

Saved in:
Format: Online
Language:English
Published: MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
non-small cell lung cancer
previously treated patients
phase I/II trial
chemotherapy
docetaxel
S-1
immunotherapy
rechallenge
retrospective analysis
pulmonary pleomorphic carcinoma
prognostic factor
glucose transporter 1
lung cancer
multiple cancers
metastasis
sequencing
mutation
genomic diagnosis
FDG-PET
immune checkpoint inhibitor
PD-1
prognosis
RAD51B methylation
PD-L1 expression
predictive biomarker
PD-1 blockade
interstitial lung disease
pulmonary fibrosis
radiology and other imaging
non-small-cell lung cancer
epidermal growth factor receptor
tyrosine kinase inhibitors
TP53 mutations
responsiveness
targeted therapy
network meta-analysis
stage IIIA-N2
surgery
immune checkpoint inhibitors
biomarker
nonsmall cell lung cancer
HIP1R
PD-L1
RUNX1
methylation
survival
EGFR-TKI
T790M
osimertinib
immune-related adverse events
endocrine disorders
tumor-bearing patients
PD-1 inhibitors
PD-L1 inhibitors
meta-analysis
nivolumab
Expanded Access Program
real-world data
daily practice
prognostic factors
NSCLC
KRAS
DNA polymerase beta
platinum-based first-line
adjuvant chemotherapy
β-catenin
lung neoplasms
nucleotide-diphosphate kinase
recurrence
unresectable
salvage surgery
oligometastasis
thema EDItEUR::M Medicine and Nursing
Online Access:ONIX_20220111_9783036501307_883
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items: Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

Similar Items